Left Arrow IconPreviousRight Arrow IconNextPlus IconExpandMinus IconCollapseMagnifying Glass IconSearch

WebView

YearNumberLinkReferenceTitleAuthors
Hide details for Published in 2015Published in 2015
207ClickN Engl J Med. 2015 Dec 24;373(26):2534-48.Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing SpondylitisBaeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB; MEASURE 1 Study Group; MEASURE 2 Study Group
206ClickMedicina (Kaunas) 2015;51(1):25-31.Predictors of mortality in patients with rheumatoid arthritis in Lithuania: Data from a cohort study over 10 years.Dadonienė J, Stropuvienė S, Stukas R, Venalis A, Sokka-Isler T.
205ClickExpert Opin Biol Ther. 2015 15(12):1677-83Cost-Effectiveness of Biologics Compared to Conventional Disease-Modifying Antirheumatic Drugs for Treatment of Rheumatoid Arthritis in Finland.Joensuu JT, Aaltonen KJ, Aronen P, Sokka T, Puolakka K, Tuompo R, Korpela M, Vasala M, Ilva K, Nordström D, Blom M.
204ClickExpert Opin Biol Ther. 2015 Nov 7:1-7. [Epub ahead of print]Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data.Nikiphorou E, Kautiainen H, Hannonen P, Asikainen J, Kokko A, Rannio T, Sokka T.
203ClickJ Rheumatol. 2015 Sep;42(9):1542-4.Rheumatoid Arthritis in the 21st Century: Treatment Patterns and Disease Activity States.Nikiphorou E, Rannio T, Sokka T.
202ClickArthritis Res Ther. 2015 Aug 20;17(1):219Ten years of change in clinical disease status and treatment in rheumatoid arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern NorwayHaugeberg G, Hansen IJ, Soldal DM, Sokka T.
201ClickArthritis Res Ther. 2015 May 9;17:117. doi: 10.1186/s13075-015-0646-xUtility of a novel inflammatory marker, GlycA, for assessment of rheumatoid arthritis disease activity and coronary atherosclerosisOrmseth MJ, Chung CP, Oeser AM, Connelly MA, Sokka T, Raggi P, Solus JF, Otvos JD, Stein CM.
200ClickPLoS One 2015 Apr 8;10(4):e0123582. doi: 10.1371/journal.pone.0123582. eCollection 2015A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritisMichelsen B, Fiane R, Diamantopoulos AP, Soldal DM, Hansen IJ, Sokka T, Kavanaugh A, Haugeberg G
199ClickJ Rheumatol. 2015 Mar;42(3):372-8. doi: 10.3899/jrheum.140853. Epub 2015 Jan 15.Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapyAaltonen KJ, Joensuu JT, Virkki L, Sokka T, Aronen P, Relas H, Valleala H, Rantalaiho V, Pirilä L, Puolakka K, Uusitalo T, Blom M, Konttinen YT, Nordström D.
198ClickNeuroimmunomodulation 2015;22(1-2):89-103. doi: 10.1159/000362735. Epub 2014 Sep 12The past versus the present, 1980-2004: reduction of mean initial low-dose, long-term glucocorticoid therapy in rheumatoid arthritis from 10.3 to 3.6 mg/day, concomitant with early methotrexate, with long-term effectiveness and safety of less than 5 mg/day.Pincus T, Sokka T, Cutolo M.
Hide details for Published in 2014Published in 2014
197ClickJ Rheumatol. 2014 Dec;41(12):2347-51. doi: 10.3899/jrheum.141443. No abstract availableHow do we classify rheumatoid arthritis in established disease - can we apply the 2010 american college of rheumatology/european league against rheumatism classification criteria?Humphreys JH, Verstappen SM, Scire CA, Uhlig T, Fautrel B, Sokka T, Symmons DP.
196ClickClin Exp Rheum. 2014 Nov-Dec;32(6):869-77. Epub 2014 Oct 20.The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA program.Grøn KL, Ornbjerg LM, Hetland ML, Aslam F, Khan NA, Jacobs JW, Henrohn D, Rasker JJ, Kauppi MJ, Lang HC, Mota LM, Aggarwal A, Yamanaka H, Badsha H, Gossec L, Cutolo M, Ferraccioli G, Gremese E, Bong Lee E, Inanc N, Direskeneli H, Taylor P, Huisman M, Alten R, Pohl C, Oyoo O, Stropuviene S, Drosos AA, Kerzberg E, Ancuta C, Mofti A, Bergman M, Detert J, Selim ZI, Abda EA, Rexhepi B, Sokka T.
195ClickJ Rheumatol. 2014 Sep;41(9):1755-60. doi: 10.3899/jrheum.131171. Epub 2014 Aug 1The role of depression, anxiety, fatigue, and fibromyalgia on the evaluation of the remission status in patients with rheumatoid arthritis.Inanc N, Yilmaz-Oner S, Can M, Sokka T, Direskeneli H.
194ClickAnn Rheum Dis 2014 Mar;73(3):492-509Recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateSmolen JS1, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D
193ClickRheumatology (Oxford) 2014 Oct;53(10):1825-9. doi: 10.1093/rheumatology/keu213. Epub 2014 May 19Smoking cessation advice by rheumatologists: results of an international survey.Naranjo A, Khan NA, Cutolo M, Lee SS, Lazovskis J, Laas K, Pandya S, Sokka T; on behalf of the QUEST-RA group.
192ClickScand J Rheumato 2014;43(4):286-90. doi: 10.3109/03009742.2013.876512. Epub 2014 Mar 24A nationwide cross-sectional overview of patients with rheumatoid arthritis followed in outpatient specialty clinics in Finland.Aaltonen K, Sokka T, Möttönen T, Korpela M, Komulainen R, Uusitalo T, Salomaa S, Uutela T, Valleala H, For The Rami Study Group.
191ClickAnn Rheum Dis 2014 Nov;73(11):2010-21. doi: 10.1136/annrheumdis-2013-203819. Epub 2013 Aug 12Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?Putrik P, Ramiro S, Kvien TK, Sokka T, Uhlig T, Boonen A; on behalf of Equity in Clinical Eligibility Criteria for RA treatment Working Group
190ClickAnn Rheum Dis. 2014 Jan;73(1):198-206Inequities in access to biologic and synthetic DMARDs across 46 European countriesPutrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, Boonen A; Working Group ‘Equity in access to treatment of rheumatoid arthritis in Europe’
Hide details for Published in 2013Published in 2013
189ClickSemin Arthritis Rheum 2013 Aug;43(1):55-62Do biologic drugs affect the need for and outcome of joint replacements in patients with rheumatoid arthritis? A register-based studyAaltonen KJ, Virkki LM, Jämsen E, Sokka T, Konttinen YT, Peltomaa R, Tuompo R, Yli-Kerttula T, Kortelainen S, Ahokas-Tuohinto P, Blom M, Nordström DC
188ClickClin Exp Rheum. 2013 May-Jun;31(3):409-14Similar clinical outcomes in rheumatoid arthritis with more versus less expensive treatment strategies. Observational data from two rheumatology clinics.Sokka T, Haugeberg G, Asikainen J, Widding Hansen IJ, Kokko A, Rannio T, Soldal DM, Hannonen P.
187ClickAnn Rheum Dis 2013 Jul;72(7):1111-2'Rheumatologist go home!' Coming up next?Uhlig T, Sokka T.
186ClickAnn Rheum Dis 2013 May;72(5):745-7Do the 2010 ACR/EULAR or ACR 1987 classification criteria predict erosive disease in early arthritis?Mäkinen H, Kaarela K, Huhtala H, Hannonen PJ, Korpela M, Sokka T.
Hide details for Published in 2012Published in 2012
185ClickAnn Rheum Dis 2012 Dec;71(12):1942-1949. Epub 2012 Apr 24Patient's global assessment of disease activity and patient's assessment of general health for rheumatoid arthritis activity assessment: are they equivalent?Khan NA, Spencer HJ, Abda EA, Alten R, Pohl C, Ancuta C, Cazzato M, Géher P, Gossec L, Henrohn D, Hetland ML, Inanc N, Jacobs JW, Kerzberg E, Majdan M, Oyoo O, Peredo-Wende RA, Selim ZI, Skopouli FN, Sulli A, Hørslev-Petersen K, Taylor PC, Sokka T; on behalf of QUEST-RA group.
184ClickRheum Dis Clin North Am May;38(2):299-310. Epub 2012 May 25.Disease activity assessment and patient-reported outcomes in patients with early rheumatoid arthritisSokka T, Rannio T, Khan NA.
183ClickArthritis Care Res (Hoboken) 2013 May;65(5):729-36Decline of mean initial prednisone dose from 10.3 to 3.6 mg/day to treat rheumatoid arthritis between 1980 and 2004 in one clinical setting, with long-term effectiveness of doses less than 5 mg/dayPincus T, Sokka T, Castrejón I, Cutolo M.
182ClickBest Practice & Research Clinical Rheumatology 26 (2012) 705–720Impact of socioeconomic gradients within and between countries on health of patients with rheumatoid arthritis (RA): Lessons from QUEST RAPolina Putrik, Tuulikki Sokka, Sofia Ramiro, Annelies Boonen
Left Arrow IconPreviousRight Arrow IconNextPlus IconExpandMinus IconCollapseMagnifying Glass IconSearch